Sign In
Buy LUMO
$4.34
+0 (+0%)
At Close: Mar 10, 2025
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
08:00am, Wednesday, 20'th Mar 2024
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t
Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
05:45pm, Thursday, 07'th Mar 2024
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q4 2023 Earnings Conference March 7, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
04:01pm, Thursday, 07'th Mar 2024
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Mo
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
09:00am, Monday, 26'th Feb 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
04:05pm, Monday, 05'th Feb 2024
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
04:05pm, Thursday, 04'th Jan 2024
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pituk
AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
04:05pm, Monday, 20'th Nov 2023
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Compan
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
09:47pm, Tuesday, 07'th Nov 2023
Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago.
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
04:35pm, Tuesday, 07'th Nov 2023
-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 –
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
09:00am, Tuesday, 26'th Sep 2023
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
08:00am, Thursday, 14'th Sep 2023
AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Announces Participation in Investor Conferences in September
04:34pm, Thursday, 07'th Sep 2023
AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time
